Clariant To Reorganize In Three Global Business Units Instead Of Five Units

Clariant AG (CLZNY.PK), a Swiss specialty chemicals firm, said Wednesday that it will slim down the number of Business Units from five to three. It will also create a new Executive Steering Committee that will include the CEO, the CFO and the Presidents of the new Business Units, who will have full P&L responsibility.

The company noted that the new structure will enable the company to reduce hierarchical layers and overall complexity across its business functions.

The new businesses will be headed by newly appointed Business Unit Presidents Angela Cackovich, Jens Cuntze, and Christian Vang.

The company is elimination the Chief Transformation Officer (CTO) and Chief Operating Officer roles. The new structure enables direct reporting lines of Clariant's Business Units to the CEO.

As a consequence of the new structure, Hans Bohnen, Chief Operating Officer, and Bernd Hoegemann, Chief Transformation Officer, have decided to step down from their current roles in the Executive Committee and will pursue their career outside the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT